Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
CureVac is a biopharmaceutical company based in Tübingen, Germany that develops therapies based on messenger RNA (mRNA). With approximately 375 employees in 2018, it was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee.
History, Technology & Companies
Explore the main themes, entities and connections around CureVac. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
vaccine announced company cvncov covid-19 mrna clinical 2020 phase vaccines develop million iii technology approximately june government candidate germany 2021
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| CureVac | Founded | 2000; 26 years ago (2000) | 1.00 | infobox |
| CureVac | Founders | Ingmar Hoerr Steve Pascolo Florian von der Muelbe Günther Jung Hans-Georg Rammensee | 1.00 | infobox |
| CureVac | Headquarters | Tübingen, Germany | 1.00 | infobox |
| CureVac | Industry | Biotechnology | 1.00 | infobox |
| CureVac | Key people | Franz-Werner Haas (CEO) Steve Pascolo (CSO) Florian von der Mulbe (COO) | 1.00 | infobox |
| CureVac | Number of employees | < 700 | 1.00 | infobox |
| CureVac | Total equity | €1.40 billion (October 2017) | 1.00 | infobox |
| CureVac | Traded as | Nasdaq: CVAC | 1.00 | infobox |
| CureVac | Type | Public | 1.00 | infobox |
| CureVac | Website | www.curevac.com | 1.00 | infobox |
| CureVac | is a | biopharmaceutical company based in Tübingen | 0.90 | text |
| CureVac | related to Acquisition | In June | 0.60 | section |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.